Incyte Corporation Stock News

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executi

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.60 per share a year ago.

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress.

The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es

Incyte Corp on Tuesday reported second-quarter profit and revenue above Wall Street estimates as demand for its blood cancer drug Jakafi and skin disorder drug Opzelura picked momentum.

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.